Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group - PubMed
9 hours ago
- #Clinical Guidelines
- #Bladder Cancer
- #Oncology
- The International Bladder Cancer Group (IBCG) provides recommendations for managing muscle-invasive bladder cancer (MIBC).
- Thorough clinical staging and multidisciplinary care are recommended for MIBC patients.
- Radical cystectomy (RC) and trimodal therapy show similar oncologic efficacy.
- Pure squamous-cell carcinoma or adenocarcinoma should be managed with upfront RC.
- Cisplatin-based neoadjuvant therapy before RC is recommended for other histologic subtypes.
- Risk-stratified adjuvant therapy approaches should be used post-RC.
- No validated predictive biomarkers exist for MIBC outside clinical trials.
- Time-to-event endpoints are recommended for perioperative therapy trials.
- Bladder-intact event-free survival is suggested for bladder preservation trials.
- Patient-reported quality-of-life endpoints should be incorporated in trials.